Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial-Reference-Cited by-同舟云学术

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial

Published:2023-06 Issue:6 Volume:18 Page:755-768
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Makharadze Tamta^ORCID,Gogishvili Miranda,Melkadze Tamar,Baramidze Ana,Giorgadze Davit,Penkov Konstantin,Laktionov Konstantin,Nemsadze Gia,Nechaeva Marina,Rozhkova Irina,Kalinka Ewa,Li Siyu,Li Yuntong,Kaul Manika,Quek Ruben G.W.,Pouliot Jean-Francois,Seebach Frank,Lowy Israel,Gullo Giuseppe,Rietschel Petra

Funder

Regeneron Pharmaceuticals

European Medicines Agency

U.S. Food and Drug Administration

Sanofi

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference25 articles.

1. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions;Xia;Oncologist,2019

2. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions;Yi;Mol Cancer,2022

3. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial;Gogishvili;Nat Med,2022

4. National Comprehensive Cancer Network. NCCN clinical practice guideline in oncology: non small cell lung cancer, version 3. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed February 28, 2023.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of anlotinib as maintenance therapy in patients with advanced non-small cell lung cancer achieving SD post first-line chemotherapy combined with immunotherapy;Journal of Chemotherapy;2024-09

2. The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions;Cancers;2024-08-19

3. Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer;Cochrane Database of Systematic Reviews;2024-08-13

4. CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy;Journal of Clinical Oncology;2024-07-10

5. The role of immunotherapy in early-stage and metastatic NSCLC;Pathology and Oncology Research;2024-07-04